Evidence map›Paper›PMID 42219812›Full record

GuidelineThe Journal of dermatology2026

Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).

Atsushi Tanemura, Naoki Oiso, Ken Okamura, Sho Hiroyasu, Yuta Araki, Lingli Yang, Yutaka Shimomura, Kenshi Yamasaki, Hiroyuki Murota, Daisuke Tsuruta and 8 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Atsushi TanemuraDepartment of Dermatology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-5239-8474
Naoki OisoDepartment of Dermatology, Kindai University Nara Hospital, Ikoma City, Nara, Japan.ORCID https://orcid.org/0000-0001-5593-6496
Ken OkamuraDepartment of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.ORCID https://orcid.org/0000-0001-7366-3233
Sho HiroyasuDepartment of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yuta ArakiDepartment of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.ORCID https://orcid.org/0000-0003-3916-1525
Lingli YangDepartment of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yutaka ShimomuraDepartment of Dermatology, Yamaguchi University Graduate School of Medicine, Ube City, Yamaguchi, Japan.ORCID https://orcid.org/0000-0001-9727-8073
Kenshi YamasakiALOOP CLINIC and LAB, Toshima-ku, Tokyo, Japan.
Hiroyuki MurotaDepartment of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-0450-1377
Daisuke TsurutaDepartment of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tamihiro KawakamiDivision of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0002-5653-4728
Kazuhiro ToriyamaDepartment of Plastic & Reconstructive Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.ORCID https://orcid.org/0000-0002-5103-189X
Akimichi MoritaDepartment of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.ORCID https://orcid.org/0000-0001-8372-3754
Shigetoshi SanoDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.ORCID https://orcid.org/0000-0002-9812-0216
Shintaro InoueCosmetic Health Science Laboratory, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-4996-5693
Kayoko MatsunagaFujita Health University, Toyoake, Aichi, Japan.ORCID https://orcid.org/0000-0001-5096-3006
Tamio SuzukiDepartment of Dermatology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Ichiro KatayamaDepartment of Pigmentation Research and Therapeutics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is a common acquired hypopigmented disorder characterized by melanocyte damage and/or loss, primarily resulting from excessive oxidative stress and dysregulated immune responses targeting melanocytes. The initial guidelines for the diagnosis and treatment of vitiligo in Japan were published in Japanese in 2012 and in English in 2013 to provide clinical evidence for vitiligo management. Since then, there has been a substantial accumulation of pathological research and therapeutic evidence. The second guidelines for the diagnosis and treatment of vitiligo in Japan (2025) are presented as an updated resource for clinicians, incorporating worldwide expert recommendations and recent advances in basic and clinical research. These guidelines aim to provide updated knowledge for individuals with vitiligo, public health professionals, scientists, and dermatologists.

Indexed as

VitiligoHumansJapanMelanocytesPractice Guidelines as TopicJapanpractice guidelines as topicskin diseasestherapeuticsvitiligo

Identifiers

PMID42219812
PMCPMC13435076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.